Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: BD is a medical technology company operating in three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2007 | Six Months Ended Mar 31, 2007 |
|---|---|---|
| Revenues | $1,575,922,000 | $3,077,449,000 |
| Operating Income | $318,064,000 | $531,894,000 |
| Net Income | $242,533,000 | $385,412,000 |
| Diluted EPS (Continuing Ops) | $0.92 | $1.44 |
| Gross Profit Margin | 51.5% | 52.1% |
| Operating Cash Flow (6mo) | $511,547,000 | |
| Total Debt | $1,164,589,000 (Short-term: $208M; Long-term: $956M) | |
| Cash and Equivalents | $409,655,000 | |
| Debt-to-Capitalization | 21.2% |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2007 revenues increased 11% year-over-year to $1.576 billion, driven by an 8% volume increase and 3% favorable foreign currency translation. Six-month revenues grew 9% to $3.077 billion.
- Profitability: Net income for the quarter rose 57% to $242.5 million compared to $154.1 million in the prior year. This improvement is largely due to the absence of a $53 million in-process research and development (IPR&D) charge recorded in the prior year for the GeneOhm acquisition.
- Acquisition Impact: The company incurred a non-deductible IPR&D charge of $114.7 million in the current six-month period related to the TriPath Imaging acquisition, reducing operating income and earnings per share.
- Discontinued Operations: The company sold its blood glucose monitoring (BGM) product line in December 2006. Results are now presented as discontinued operations, contributing a net gain of $6.99 million in Q2 2007.
- Segment Performance:
- Medical: Revenues up 10%; Operating income up 14%.
- Diagnostics: Revenues up 11%; Operating income up 89% (primarily due to the absence of the prior year's GeneOhm charge).
- Biosciences: Revenues up 13%; Operating income up 21%.
Guidance, Outlook, and Risks
- Outlook: Management expects gross profit margins to improve by approximately 70 basis points in fiscal 2007. Selling and administrative expenses are expected to increase by about 40 basis points as a percentage of revenue. Research and development expenses are anticipated to increase by approximately 35% on a reported basis.
- Capital Allocation: Capital expenditures for 2007 are expected to range between $600 million and $650 million. The company repurchased $225 million of common stock in the first six months of 2007, with authorization remaining for an additional 4.0 million shares.
- Legal Proceedings:
- Antitrust: Two new class action antitrust suits were filed in early 2007, bringing the total to 10. These are expected to be consolidated in Multi-District Litigation.
- bioMérieux Dispute: bioMérieux initiated arbitration against BD subsidiary GeneOhm regarding patent rights for MRSA detection and alleged breach of a separate license agreement for BACTEC products. BD intends to vigorously defend these claims.
- Government Investigations: Ongoing investigations by the U.S. Attorney's Office in Dallas and Attorneys General in Connecticut and Illinois regarding trade organization participation and supplier transactions.
- Market Risks: Exposure to foreign currency fluctuations, raw material costs (specifically oil-based resins), and potential impacts of new product introductions by competitors (e.g., inhaled insulin).
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress and revenue contribution of the TriPath Imaging acquisition, which incurred a significant $115 million IPR&D charge.
- Legal Exposure: Monitor the status of the 10 antitrust class action lawsuits and the bioMérieux arbitration, as unfavorable outcomes could result in material charges or loss of patent rights.
- Margin Sustainability: Assess whether the reported gross margin improvements (driven by product mix and productivity) can be sustained amidst rising raw material costs and currency headwinds.
- Discontinued Operations: Confirm that the BGM divestiture is fully closed and that no further adjustments to the gain on sale are expected.
- Debt Structure: Review the company's debt-to-capitalization ratio (21.2%) and the utilization of its $1 billion syndicated credit facility to ensure liquidity remains robust.